Johns Hopkins Center for Health Security, World Economic Forum and Bill & Melinda Gates Foundation Host Pandemic Exercise and Livestream
The Johns Hopkins Center for Health Security, with the World Economic Forum and the Bill & Melinda Gates Foundation, will host Event 201 , a multimedia global pandemic exercise on Friday, Oct. 18, 2019, in New York City. The public may register and participate in the simultaneous virtual exercise in English, 8:50 a.m.-12:30 p.m. EDT at centerforhealthsecurity.org/event201/. The exercise underscores the need for global public-private cooperation to mitigate economic and societal impacts of severe pandemics.
In recent years, the world has seen a growing number of epidemic events, about 200 per year, which strain limited resources. A large global pandemic would be disruptive to health, economies, and society. Economic studies show that pandemics could be the cause of an average annual economic loss of 0.7% of global GDP—or $570 billion.
Event 201, played by 15 leaders of businesses, governments, and public health, will illustrate realistic policy problems that must be addressed under pressure during a pandemic. At the video-driven exercise, players will be presented with a scenario that reveals unresolved and controversial policy and economic issues that could be solved with sufficient political will, financial investment, and attention.
“In addition to challenging health and health systems, pandemics can cause severe cascading economic and societal consequences,” said Tom Inglesby, MD, director of the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health. “Neither governments nor private industries alone can adequately respond to a severe pandemic; they must work together. We’ve designed Event 201 to engage leaders in compelling ways to help them understand the decisions needed to prepare for and respond to biological threats.”
“Outbreaks of infectious disease are inevitable, but the economic damage they cause is not,” said Ryan Morhard, project lead for Global Health Security at the World Economic Forum. “Sustained attention from a broad multistakeholder coalition is needed in advance of a severe pandemic to save lives and minimize economic and societal consequences.”
Chris Elias, president of global development at the Gates Foundation, noted that “Event 201 and its predecessor simulations like Clade X are crucial tools to understand not only what is needed to effectively respond to global public health crises, but also the consequences of what happens when we are not prepared.”
The exercise is supported by funding from the Open Philanthropy Project.
More information is at centerforhealthsecurity.org/event201, #Event201, @JHSPH_CHS, @wef and @gatesfoundation.
EVENT 201 IS A FICTIONAL EXERCISE AND DISEASE
Editor’s note: RSVP for a confirmed seat, information about camera and recording limitations; access same day to video, graphics, audio, photos and interviews. See Event 201 media advisory and other materials.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005859/en/
Contact information
Media:
Carol Miller
Communications Strategic Lead, Event 201
Johns Hopkins Center for Health Security
carolmiller@jhc.edu 1-202-306-0130
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release
Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 14:30:00 EEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom